Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7406600 | 0.82 | KDM4E (0.36) | MAOAKDM1AMAOBRAB9ANPC1 | |
| SCHEMBL7407044 | 0.82 | KDM1A (0.47) | KDM1AMAOBSLC6A4 | |
| SCHEMBL7408480 | 0.82 | KDM1A (0.33) | MAOAKDM1AMAOB | |
| SCHEMBL1127119 | 0.80 | MAOB (0.39) | MAOAKDM1AMAOBSLC6A4 | |
| SCHEMBL7405556 | 0.74 | KDM1A (0.43) | MAOAKDM1AMAOB | |
| SCHEMBL7403912 | 0.72 | KDM1A (0.40) | MAOAKDM1AMAOBSLC6A4 | |
| SCHEMBL8482401 | 0.71 | ATM (0.40) | RAB9ANPC1MAPTSLC6A4 | |
| SCHEMBL7409213 | 0.71 | KDM1A (0.31) | KDM1ASLC6A4 | |
| SCHEMBL7968510 | 0.69 | ADRA2A (0.36) | RAB9ANPC1MAPT | |
| SCHEMBL7209332 | 0.65 | CLK4 (0.44) | CLK4MAOADYRK1AKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1453847-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003050132-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | Q6ZSR9, ACSL6, RPS4Y1 | CLK4 3870/4885MAOA 1537/4885DYRK1A 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.